NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
Clinical Trials
20 trialsNCT05306301 2026-03-06
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Active not recruiting
NCT05268003 2026-03-05
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07224100 2026-02-20
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
Phase 2 Recruiting
NCT03147612 2026-02-17
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01424982 2025-12-05
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04188405 2025-11-20
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04070443 2025-11-18
TIPI
Centre Leon Berard
Phase 2 Active not recruiting
NCT04233346 2025-04-04
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
Phase 2 Active not recruiting
NCT02398825 2025-01-17
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT04160546 2024-12-31
ResToP
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Active not recruiting
NCT04554459 2024-08-14
Pona-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 2 Terminated
NCT04845035 2024-02-22
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT03807479 2023-09-14
PONS
GWT-TUD GmbH
Phase 2 Terminated
NCT01641107 2021-11-30
LAL1811
Incyte Corporation
Phase 2 Completed
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04709731 2021-02-03
CarPAs
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Phase 2 Unknown
NCT01207440 2021-02-02
PACE
Takeda
Phase 2 Completed
NCT04043676 2019-08-02
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Fundación Teófilo Hernando, Spain
Phase 2 Unknown